Charles Schoch

Charles Schoch is recorded as CFO at Candel Therapeutics, Inc. (CADL) since June 20, 2025. The newest filing on record that lists Charles Schoch as CFO at Candel Therapeutics, Inc. (CADL) is dated April 29, 2026. Candel Therapeutics, Inc. reported in an 8-K filed June 23, 2025 that Charles Schoch was appointed Chief Financial Officer, effective June 20, 2025. Candel Therapeutics, Inc. reported in an 8-K filed January 12, 2024 that Charles Schoch was appointed interim Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024. The proxy statement of Candel Therapeutics, Inc. reports total compensation of $1,470,817 for Charles Schoch in fiscal 2025, including a base salary of $398,500. Candel Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Candel Therapeutics, Inc. includes Paul Peter Tak (CEO and Board Member), Jason Amello (CFO), Diem Nguyen, Ph.D. (Board Member) and 7 others.